HIL Applied Medical Revenue and Competitors

Jerusalem,

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • HIL Applied Medical's estimated annual revenue is currently $7.3M per year.(i)
  • HIL Applied Medical's estimated revenue per employee is $251,000

Employee Data

  • HIL Applied Medical has 29 Employees.(i)
  • HIL Applied Medical grew their employee count by 4% last year.

HIL Applied Medical's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M40-18%$10MN/A
#2
$24.8M9929%N/AN/A
#3
$84.1M0N/A$1.2MN/A
#4
$35.6M14230%N/AN/A
#5
$57.5M2296%N/AN/A
#6
$52.7M16825%$129.6MN/A
#7
$21.1M84-3%N/AN/A
#8
$61.2M244-13%N/AN/A
#9
$60.6M19320%$115.5MN/A
#10
$56.2M179-3%$122.9MN/A
Add Company

What Is HIL Applied Medical?

HIL Applied Medical is an R&D-stage medical-technology startup, on an accelerated growth path. We are developing a new class of compact, high-performance cancer proton-therapy systems. HIL applies a patented approach to particle acceleration and beam delivery, combining nano-technology with Nobel-Prize-winning ultra-high-intensity lasers and ultra-fast magnets. These technological breakthroughs enable meaningful reduction in the size, complexity and cost of proton therapy systems, without compromising clinical utility. Thus HIL aims to enable, for the first time, a single-room add-on proton therapy solution that is truly cost-effective. Affordable single-room systems are key to widespread adoption of this important therapy, and an enabler of a $10BB market (US). HIL Applied Medical is a privately-held company, backed by VCs and global strategic partners. We are headquartered in the High-Tech Park, Givat Ram, Jerusalem, Israel; and have a wholly-owned subsidiary in Reno, Nevada (United States).

keywords:N/A

N/A

Total Funding

29

Number of Employees

$7.3M

Revenue (est)

4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

HIL Applied Medical News

2022-04-06 - Applied Molecular Transport Announces Publication in Tissue ...

AMT-126 is a novel GI-selective, oral fusion of hIL-22 and AMT's proprietary carrier molecule currently in development for diseases related to...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$6.6M29-12%N/A
#2
$7.3M297%N/A
#3
$3.6M3129%N/A
#4
$6.2M31-6%N/A
#5
N/A34-8%N/A